Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates

Journal of Nuclear Medicine

Volumn 56, Issue 4, 2015, Pages 628-634

  Banerjee, Sangeeta Ray ^a   Foss, Catherine A ^a   Pullambhatla, Mrudula ^a   Wang, Yuchuan ^a   Srinivasan, Senthamizhchelvan ^a   Hobbs, Robert F ^a   Baidoo, Kwamena E ^b   Brechbiel, Martin W ^b   Nimmagadda, Sridhar ^a   Mease, Ronnie C ^a   Sgouros, George ^a   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

86Y DOTA; Molecular imaging; PET; PSMA; Radiopharmaceutical therapy

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN; YTTRIUM 86; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RETENTION; DRUG UPTAKE; IN VIVO STUDY; INHIBITION CONSTANT; ISOTOPE LABELING; KIDNEY; KIDNEY CORTEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; ANIMAL; BABOON; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DIAGNOSTIC USE; HUMAN; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOMETRY; TIME; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; PAPIO; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOMETRY; RADIOPHARMACEUTICALS; SOFTWARE; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 84928237478     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.149062     Document Type: Article

References (36)

1. 86Y based PET radiopharmaceuticals: radiochemistry and biological applications. Med Chem. 2011;7:380-388.
2. 86Y using a small biomedical cyclotron. Nucl Med Biol. 2005;32:891-897.
3. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
4. 90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1038-1046.
5. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386-1392.
6. 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44:1148-1155.
7. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-539.
8. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540-547.
9. OlsonWC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2:182-190.
10. Schülke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA. 2003;100:12590-12595.
11. Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13:951-962.
12. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333-5341.
13. 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-1891.
14. Kulkarni H, Weineisen M, Mueller D, et al. First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer. J Nucl Med. 2014;55(suppl 1):10.
15. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
16. Banerjee SR, Pullambhatla M, Shallal H, Lisok A, Mease RC, Pomper MG. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget. 2011;2:1244-1253.
17. Banerjee SR, Pullambhatla M, Byun Y, et al. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl. 2011;50:9167-9170.
18. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517.
19. Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther. 2008;7:974-982.
20. Kam BL, Teunissen JJ, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S103-S112.
21. Chen Z, Penet MF, Nimmagadda S, et al. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano. 2012;6:7752-7762.
22. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
23. Olszewski RT, Bukhari N, Zhou J, et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem. 2004;89:876-885.
24. Schwartz J, Jaggi JS, O'Donoghue JA, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56:721-733.
25. Woodard HQ, Bigler RE, Freed B. Letter: expression of tissue isotope distribution. J Nucl Med. 1975;16:958-959.
26. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med. 2009;50:477-484.
27. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
28. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
29. Baechler S, Hobbs RF, Boubaker A, et al. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy. Med Phys. 2012;39:6118-6128.
30. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009;50:1844-1847.
31. 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia. 2002;16:60-66.
32. Baur B, Solbach C, Andreolli E, Winter G, Machulla HJ, Reske SN. Synthesis, radiolabelling and in vitro characterization of the gallium-68-, yttrium-90- and lutetium-177-labelled PSMA ligand, CHX-A″-DTPA-DUPA-Pep. Pharmaceuticals (Basel). 2014;7:517-529.
33. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-4601.
34. Tagawa ST, Akhtar NH, Nikolopoulou A, et al. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Front Oncol. 2013;3:214.
35. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.
36. 177Lu? J Nucl Med. 2005;46:634-641.